256 related articles for article (PubMed ID: 31868223)
1. Assessment of Maternal and Fetal Dolutegravir Exposure by Integrating Ex Vivo Placental Perfusion Data and Physiologically-Based Pharmacokinetic Modeling.
Freriksen JJM; Schalkwijk S; Colbers AP; Abduljalil K; Russel FGM; Burger DM; Greupink R
Clin Pharmacol Ther; 2020 Jun; 107(6):1352-1361. PubMed ID: 31868223
[TBL] [Abstract][Full Text] [Related]
2. Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study).
Waitt C; Orrell C; Walimbwa S; Singh Y; Kintu K; Simmons B; Kaboggoza J; Sihlangu M; Coombs JA; Malaba T; Byamugisha J; Amara A; Gini J; Else L; Heiburg C; Hodel EM; Reynolds H; Mehta U; Byakika-Kibwika P; Hill A; Myer L; Lamorde M; Khoo S
PLoS Med; 2019 Sep; 16(9):e1002895. PubMed ID: 31539371
[TBL] [Abstract][Full Text] [Related]
3. Prediction of Maternal and Fetal Pharmacokinetics of Dolutegravir and Raltegravir Using Physiologically Based Pharmacokinetic Modeling.
Liu XI; Momper JD; Rakhmanina NY; Green DJ; Burckart GJ; Cressey TR; Mirochnick M; Best BM; van den Anker JN; Dallmann A
Clin Pharmacokinet; 2020 Nov; 59(11):1433-1450. PubMed ID: 32451908
[TBL] [Abstract][Full Text] [Related]
4. ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing.
Moore CL; Turkova A; Mujuru H; Kekitiinwa A; Lugemwa A; Kityo CM; Barlow-Mosha LN; Cressey TR; Violari A; Variava E; Cotton MF; Archary M; Compagnucci A; Puthanakit T; Behuhuma O; Saϊdi Y; Hakim J; Amuge P; Atwine L; Musiime V; Burger DM; Shakeshaft C; Giaquinto C; Rojo P; Gibb DM; Ford D;
BMC Infect Dis; 2021 Jan; 21(1):5. PubMed ID: 33446115
[TBL] [Abstract][Full Text] [Related]
5. Placental transfer and tissue accumulation of dolutegravir in the ex vivo human cotyledon perfusion model.
Mandelbrot L; Ceccaldi PF; Duro D; Lê M; Pencolé L; Peytavin G
PLoS One; 2019; 14(8):e0220323. PubMed ID: 31408460
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and Placental Transfer of Elvitegravir, Dolutegravir, and Other Antiretrovirals during Pregnancy.
Rimawi BH; Johnson E; Rajakumar A; Tao S; Jiang Y; Gillespie S; Schinazi RF; Mirochnick M; Badell ML; Chakraborty R
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28348149
[TBL] [Abstract][Full Text] [Related]
7. Placental transfer of the HIV integrase inhibitor dolutegravir in an ex vivo human cotyledon perfusion model.
Schalkwijk S; Greupink R; Colbers AP; Wouterse AC; Verweij VG; van Drongelen J; Teulen M; van den Oetelaar D; Burger DM; Russel FG
J Antimicrob Chemother; 2016 Feb; 71(2):480-3. PubMed ID: 26538508
[TBL] [Abstract][Full Text] [Related]
8. Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV.
Mulligan N; Best BM; Wang J; Capparelli EV; Stek A; Barr E; Buschur SL; Acosta EP; Smith E; Chakhtoura N; Burchett S; Mirochnick M;
AIDS; 2018 Mar; 32(6):729-737. PubMed ID: 29369162
[TBL] [Abstract][Full Text] [Related]
9. Enhanced Solubility and Bioavailability of Dolutegravir by Solid Dispersion Method: In Vitro and In Vivo Evaluation-a Potential Approach for HIV Therapy.
Chaudhary S; Nair AB; Shah J; Gorain B; Jacob S; Shah H; Patel V
AAPS PharmSciTech; 2021 Apr; 22(3):127. PubMed ID: 33835317
[TBL] [Abstract][Full Text] [Related]
10. Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial.
Bollen PDJ; Moore CL; Mujuru HA; Makumbi S; Kekitiinwa AR; Kaudha E; Parker A; Musoro G; Nanduudu A; Lugemwa A; Amuge P; Hakim JG; Rojo P; Giaquinto C; Colbers A; Gibb DM; Ford D; Turkova A; Burger DM;
Lancet HIV; 2020 Aug; 7(8):e533-e544. PubMed ID: 32763217
[TBL] [Abstract][Full Text] [Related]
11. Bioequivalence and Food Effect Assessment of 2 Fixed-Dose Combination Formulations of Dolutegravir and Lamivudine.
Dumitrescu TP; Peddiraju K; Fu C; Bakshi K; Yu S; Zhang Z; Tenorio AR; Spancake C; Joshi S; Wolstenholme A; Adkison K
Clin Pharmacol Drug Dev; 2020 Feb; 9(2):189-202. PubMed ID: 31724343
[TBL] [Abstract][Full Text] [Related]
12. Prediction of Fetal Darunavir Exposure by Integrating Human Ex-Vivo Placental Transfer and Physiologically Based Pharmacokinetic Modeling.
Schalkwijk S; Buaben AO; Freriksen JJM; Colbers AP; Burger DM; Greupink R; Russel FGM
Clin Pharmacokinet; 2018 Jun; 57(6):705-716. PubMed ID: 28744795
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging people living with HIV.
Courlet P; Stader F; Guidi M; Alves Saldanha S; Stoeckle M; Cavassini M; Battegay M; Buclin T; Decosterd LA; Marzolini C;
AIDS; 2020 Jan; 34(1):103-108. PubMed ID: 31490233
[TBL] [Abstract][Full Text] [Related]
14. Placental transfer of the integrase strand inhibitors cabotegravir and bictegravir in the ex-vivo human cotyledon perfusion model.
Pencolé L; Lê MP; Bouchet-Crivat F; Duro D; Peytavin G; Mandelbrot L
AIDS; 2020 Nov; 34(14):2145-2149. PubMed ID: 32796211
[TBL] [Abstract][Full Text] [Related]
15. Early experience of dolutegravir pharmacokinetics in pregnancy: high maternal levels and significant foetal exposure with twice-daily dosing.
Lewis JM; Railton E; Riordan A; Khoo S; Chaponda M
AIDS; 2016 May; 30(8):1313-5. PubMed ID: 27128333
[No Abstract] [Full Text] [Related]
16. Pharmacokinetics of HIV-Integrase Inhibitors During Pregnancy: Mechanisms, Clinical Implications and Knowledge Gaps.
van der Galiën R; Ter Heine R; Greupink R; Schalkwijk SJ; van Herwaarden AE; Colbers A; Burger DM
Clin Pharmacokinet; 2019 Mar; 58(3):309-323. PubMed ID: 29915921
[TBL] [Abstract][Full Text] [Related]
17. Dolutegravir pharmacokinetics in the genital tract and colorectum of HIV-negative men after single and multiple dosing.
Greener BN; Patterson KB; Prince HM; Sykes CS; Adams JL; Dumond JB; Shaheen NJ; Madanick RD; Dellon ES; Cohen MS; Kashuba AD
J Acquir Immune Defic Syndr; 2013 Sep; 64(1):39-44. PubMed ID: 23945251
[TBL] [Abstract][Full Text] [Related]
18. Point-of-Care Detection of Nonadherence to Antiretroviral Treatment for HIV-1 in Resource-Limited Settings Using Drug Level Testing for Efavirenz, Lopinavir, and Dolutegravir: A Validation and Pharmacokinetic Simulation Study.
Hermans LE; Nijhuis M; Tempelman HA; Houts T; Schuurman R; Burger DM; Wensing AMJ; ter Heine R
J Acquir Immune Defic Syndr; 2021 Aug; 87(4):1072-1078. PubMed ID: 34153013
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF).
Nabisere R; Musaazi J; Denti P; Aber F; Lamorde M; Dooley KE; Aarnoutse R; Sloan DJ; Sekaggya-Wiltshire C
Trials; 2020 Feb; 21(1):181. PubMed ID: 32054536
[TBL] [Abstract][Full Text] [Related]
20. The effect of veno-arterial extracorporeal oxygenation and nasogastric tube administration on the pharmacokinetic profile of abacavir, lamivudine and dolutegravir: a case report.
Blackman AL; Heil EL; Devanathan AS; Pandit NS
Antivir Ther; 2020; 25(2):115-119. PubMed ID: 32341207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
